Literature DB >> 33611704

Neurosurgical involvement in clinical trials for CNS tumors.

Michael A Vogelbaum1, Ian F Parney2, J Bradley Elder3, Daniel Cahill4.   

Abstract

INTRODUCTION: Most clinical trials in neurooncology are led by investigators primarily trained in neurology or medical oncology. While neurosurgeons are trained to be problem-solvers and innovators, research training has historically been focused on laboratory-based discovery approaches and formalized training in prospective clinical trials research is not part of routine graduate training.
METHODS: We reviewed literature that demonstrates that innovation and problem-solving are integral to the practice of neurosurgery cite multiple examples of advances in technique and technology that may have had an empirical origin but that led to prospective clinical trials resulting in change in practice.
RESULTS: Neurosurgeons have developed and led both traditional (clinical outcome-oriented) and translational prospective clinical trials that have evaluated the best use of currently available therapeutics or tested the ability of novel therapeutics to alter the biology and/or course of disease.
CONCLUSIONS: In this review, we focus on a number of the recently developed technologies and therapeutics that were evaluated in clinical trials led or co-led by neurosurgeons. We also highlight some of the barriers that need to be addressed in order to foster neurosurgical participation and leadership in the prospective development of novel therapeutics.

Entities:  

Keywords:  Brain metastases; Clinical trials; Gliomas; Neurosurgery

Year:  2021        PMID: 33611704     DOI: 10.1007/s11060-020-03438-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications.

Authors:  P M Black; T Moriarty; E Alexander; P Stieg; E J Woodard; P L Gleason; C H Martin; R Kikinis; R B Schwartz; F A Jolesz
Journal:  Neurosurgery       Date:  1997-10       Impact factor: 4.654

2.  Erratum. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

Authors:  Leland Rogers; Peixin Zhang; Michael A Vogelbaum; Minesh P Mehta
Journal:  J Neurosurg       Date:  2018-12-01       Impact factor: 5.115

3.  Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

Authors:  Sandeep Kunwar; Susan Chang; Manfred Westphal; Michael Vogelbaum; John Sampson; Gene Barnett; Mark Shaffrey; Zvi Ram; Joseph Piepmeier; Michael Prados; David Croteau; Christoph Pedain; Pamela Leland; Syed R Husain; Bharat H Joshi; Raj K Puri
Journal:  Neuro Oncol       Date:  2010-02-04       Impact factor: 12.300

4.  Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats.

Authors:  Jeffrey W Degen; Stuart Walbridge; Alexander O Vortmeyer; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2003-11       Impact factor: 5.115

5.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

6.  Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article.

Authors:  Andrew E Sloan; Manmeet S Ahluwalia; Jose Valerio-Pascua; Sunil Manjila; Mark G Torchia; Stephen E Jones; Jeffrey L Sunshine; Michael Phillips; Mark A Griswold; Mark Clampitt; Cathy Brewer; Jennifer Jochum; Mary V McGraw; Dawn Diorio; Gail Ditz; Gene H Barnett
Journal:  J Neurosurg       Date:  2013-04-05       Impact factor: 5.115

Review 7.  High-Intensity Focused Ultrasound Ablation Therapy of Gliomas.

Authors:  Ryan D Alkins; Todd G Mainprize
Journal:  Prog Neurol Surg       Date:  2018-07-10

8.  Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin.

Authors:  Gregory J A Murad; Stuart Walbridge; Paul F Morrison; Kayhan Garmestani; Jeffrey W Degen; Martin W Brechbiel; Edward H Oldfield; Russell R Lonser
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 13.801

9.  Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.

Authors:  Sabine Mueller; Mei-Yin Polley; Benjamin Lee; Sandeep Kunwar; Christoph Pedain; Eva Wembacher-Schröder; Stephan Mittermeyer; Manfred Westphal; John H Sampson; Michael A Vogelbaum; David Croteau; Susan M Chang
Journal:  J Neurooncol       Date:  2010-06-20       Impact factor: 4.130

10.  Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.

Authors:  Ian F Parney; Sandeep Kunwar; Michael McDermott; Mitchel Berger; Michael Prados; Soonmee Cha; David Croteau; Raj K Puri; Susan M Chang
Journal:  J Neurosurg       Date:  2005-02       Impact factor: 5.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.